openPR Logo
Press release

Obesity - Pipeline Review, H2 2016: Ken Research

04-21-2017 06:47 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Ken Research Pvt Ltd

Global Markets Direct’s, ‘Obesity - Pipeline Review, H2 2016’, provides an overview of the Obesity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Obesity

The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects

The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Obesity

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Obesity

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

Ken Research is a Global aggregator and publisher of Market intelligence research reports, equity reports, data base directories and economy reports. Our market research reports provides market sizing analysis, insights on promising industry segments, competition, future outlook and growth drivers in the space. The company is engaged in data analytics and aids clients in due-diligence, product expansion, plant setup, acquisition intelligence to all the other gamut of objectives through our research focus.


This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Obesity - Pipeline Review, H2 2016: Ken Research here

News-ID: 510074 • Views: 310

More Releases from Ken Research Pvt Ltd

Service Offerings, Network Coverage, Pricing, Technological Advancements, Delive …
E-Commerce transactions reached a new peak due to the lockdown restrictions issued in the country, with daily usage items, medicines, FMCG goods, retail items being ordered online. Shipper has tied up with the technological partner which ensures that the company can track assets-real time and have access to biggest trucking network. Various e-commerce and technological start-ups such as Kargo technologies, Shipper, Logisly, Wareix, Sicepat Express, Ritase and Crewdible are being supported by
Wide Ranging Preamble Of Due Diligence Market Outlook: Ken Research
Market due diligence, dissimilar other characteristics of diligence, does not base its discoveries on information delivered by the establishment. Instead, market due diligence comprises congregation data from industry experts, competitors, customers, and occasionally suppliers and other third-party market contestants. In niche markets, it is important to gain the perspective not only of clients, lost accounts, and prospects, but third-party market authorities, and, most importantly, direct and indirect participants. Although, reliant on
Effective Increasing Insights Of Financial Brokerage Market Outlook: Ken Researc …
The Financial Brokerage market was effectively witnessed in an increasing stage wherein the market observed slow growth throughout the review duration of 2013-2018. Throughout 2013-2015, a decrease in growth rate was witnessed across Indonesia Financial Brokerage market owing to the external aspects of slowdown across Chinese economy, placing of boundaries on funds borrowing by Federal Reserve and capital flight from Indonesia’s region which led to augmenting the interest rates by
Effective Changes In Automobile Leasing And Vehicle Loan Market Outlook: Ken Res …
The Car finance is prearranged by financing corporates or dedicated car producers. It comprises the quite a few financial products likewise loans & leases, which qualifies the customers to advantage the car. In addition, the car finance products & services are predominantly disseminated through the original equipment manufacturers (OEMs), banks, credit unions, brokers, and numerous other financial institutions. Furthermore, the car or auto financing or vehicle loan is services

All 5 Releases

More Releases for Obesity

Fast Food and Obesity
Most of the fast food in the market contains a large quantity of sugar, #carbs and fats with a lesser quantity of vitamins and minerals. The unhealthy food ingredients in the fast food are further increased with increased portion size. The person will still consume the whole meal regardless of being completely full. People cannot stop ravishing on fast food because it is available for low cost and in close
Obesity Management Congress 2018
Obesity can be managed by combination of lifestyle change, exercise and healthy diet plans. In case of severe Obesity bariatric surgery and medications will be employed. People who have gone through bariatric surgery which have suppressed hunger and the mechanism for which causes obesity based type 2 diabetes is reversed and it also causes sixty to eighty percent weight loss for a long term. But it has it cons
Obesity Therapeutic and Disease Pipeline Review H2
Summary Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery. Report Highlights Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development
Obesity Management Market | Global Industry Analysis 2027
High costs involved in the research & development (R&D) of obesity drugs, coupled with limited financial support, are collectively a great challenge for adoption of obesity management solutions. Additionally, long gestation time needed for R&D activities, and the inclusion of clinical trials required to test these drugs hikes the expenditure significantly. Considering this scenario, manufacturers are being cautious while seeking better return on investments. In the long run, risks and
Obesity Treatment Market driven by rise in childhood obesity rates
Obesity is a disorder in which excess body fat gets accumulated to such extent that it may have negative effects on health. It occurs over time when people eat more calories than they utilize. The reasons for obesity can be medical problems, inactivity, genetics, family lifestyle, unhealthy diet, medications, age, and pregnancy. Being obese increases the risk of diabetes, heart disease, stroke, arthritis, and some type of cancers. Obesity treatment
Diabetes & Obesity Drug Development Pipeline Review, 2016
ReportsWorldwide has announced the addition of a new report title Diabetes & Obesity Drug Development Pipeline Review, 2016 to its growing collection of premium market research reports. The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications.